AACR Annual Meeting 2018: Off-the-shelf CAR T-cell Immunotherapy – Are we There Yet?

A study presented at the AACR Annual Meeting 2018 discussed preliminary data on an off-the-shelf, T-cell receptor (TCR)-less, dual-targeted CD19-CAR T-cell product, FT819. In proof-of-concept preclinical studies, FT819 was found …

Read More

AACR Annual Meeting 2018: Novel Immunotherapy Combinations to Combat Resistance to Checkpoint Inhibition

An exciting area in drug development, immunotherapy is being increasingly utilized by patients with different cancer types. These treatments work by stimulating the patient’s immune system to effectively target and …

Read More

How Does Lung Cancer Evade the Immune System?

Much has been written, including on this blog, about the rapidly expanding use of immunotherapy to treat an increasing array of cancer types, including lung cancer. The development of these new treatments, which harness a patient’s immune system to fight cancer, is built upon many years of basic research in the fields of immunology and cancer biology.

Read More

Recent Advances in Measuring Response to Immune Checkpoint Inhibitors

In recent years, the U.S. Food and Drug Administration has approved immune checkpoint inhibitors, a class of immunotherapy, to treat 10 different types of cancer, in addition to solid tumors located anywhere in the body that have certain DNA damage and repair-related biomarkers. However, only a small percentage of patients respond to these treatments, and they can have significant side effects. Researchers are looking for biomarkers that can identify patients who are likely to respond to immune checkpoint inhibitors.

Read More

FDA Approvals for Liver and Stomach Cancer Extend the Reach of Immunotherapy

Last week, the U.S. Food and Drug Administration (FDA) increased the number of types of cancer for which immunotherapeutics known as checkpoint inhibitors are a treatment option when it expanded the approved uses of nivolumab (Opdivo) and pembrolizumab (Keytruda) to include certain patients with liver cancer and stomach cancer, respectively.

Read More

Lessons Learned From Combining Anti-OX40 and Anti-PD1 Immunotherapies

A pair of studies published recently in journals of the American Association for Cancer Research bring to our attention the unexpected negative consequences of combining two immunotherapeutics concurrently, and discuss the mechanisms behind improved antitumor effects and survival outcomes with sequential administration of the two drugs.

Read More